PALO ALTO, Calif. (AP) — PALO ALTO, Calif. (AP) — BridgeBio Pharma Inc. (BBIO) on Monday reported a loss of $152.2 million in its second quarter.
On a per-share basis, the Palo Alto, California-based company said it had a loss of 78 cents.
The results missed Wall Street expectations. The average estimate of seven analysts surveyed by Zacks Investment Research was for a loss of 64 cents per share.
The rare disease drug developer posted revenue of $243.7 million in the period, beating Street forecasts. Six analysts surveyed by Zacks expected $222.6 million.
BridgeBio Pharma shares have increased 11% since the beginning of the year. In the final minutes of trading on Monday, shares hit $85, a climb of 82% in the last 12 months.
_____
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on BBIO at https://www.zacks.com/ap/BBIO
Copyright © 2026 The Associated Press. All rights reserved. This material may not be published, broadcast, written or redistributed.
